SHIRLEY, NY, August 27, 2026 /24-7PressRelease/ — Creative Biolabs has updated its in vivo CAR-T development portfolio to provide research teams with additional options for investigating direct immune cell engineering. The portfolio includes viral and non-viral development approaches that can be adapted to different CAR-T research objectives and preclinical study requirements.
As CAR-T research continues to evolve, conventional ex vivo development can present practical challenges for some programs. Processes involving cell collection, genetic modification, expansion, characterization, and subsequent administration may require considerable time, specialized infrastructure, and coordinated manufacturing workflows. These factors have encouraged researchers to investigate alternative approaches that may reduce reliance on certain ex vivo processing steps.
In vivo CAR-T research represents one such direction. Rather than engineering immune cells through an ex vivo workflow, this approach investigates the delivery of CAR-encoding genetic material directly to selected cells in vivo. Its development, however, involves several technical considerations, including delivery platform selection, cell targeting, genetic cargo design, expression control, biodistribution, and functional assessment.
To support studies in this area, Creative Biolabs offers an in vivo CAR-T development solution that brings together multiple development and evaluation capabilities. The company’s comprehensive in vivo CAR-T development solution can be tailored according to project-specific factors such as target cell populations, CAR constructs, delivery preferences, and preclinical research plans.
Delivery strategy is an important consideration because individual research programs may differ in their payload requirements, targeting objectives, and desired expression profiles. Creative Biolabs therefore provides both non-viral and viral development options, allowing researchers to assess approaches that align with their study designs.
Through its in vivo non-viral CAR-T development service, Creative Biolabs supports projects exploring non-viral methods for delivering CAR-encoding genetic material. This option can be considered by research teams evaluating alternative delivery strategies and investigating ways to address challenges associated with targeted in vivo immune cell engineering.
The company’s in vivo viral vector-based CAR-T cell development service supports studies using viral delivery approaches. Researchers can incorporate this route into development programs based on factors such as CAR design, target cells, delivery requirements, and planned preclinical evaluation.
By integrating these capabilities within a broader development framework, Creative Biolabs aims to help research teams coordinate different stages of in vivo CAR-T studies and evaluate suitable development routes. The updated portfolio also provides flexibility for researchers comparing viral and non-viral approaches according to the requirements of individual projects.
With continued interest in in vivo immune cell engineering, Creative Biolabs is refining its CAR-T research services to support scientists investigating emerging development strategies and potential approaches to existing manufacturing and delivery challenges.
Learn more about Creative Biolabs’ in vivo CAR-T development options and explore research support based on specific project requirements: https://www.creative-biolabs.com/car-t/in-vivo-car-t-development-solution.htm.
Services are intended for research use only and are not provided to individuals.
About Creative Biolabs
Creative Biolabs is a biotechnology company with extensive cell therapy experience, providing customized CAR-T development solutions for global research programs.
—
For the original version of this press release, please visit 24-7PressRelease.com here
Legal Disclaimer: The content on this page is syndicated from independent third-party providers. Kyrion Media makes no warranties or representations regarding the accuracy, completeness, legality, or reliability of the information, including text, images, videos, or licenses. If you are affiliated with this content or have any complaints, copyright concerns, or requests for removal, please contact us at [email protected] with the specific URL of the content in question. We will review and address valid requests promptly.
